Ignite Creation Date:
2025-12-24 @ 4:48 PM
Ignite Modification Date:
2026-02-26 @ 6:52 AM
Study NCT ID:
NCT02306850
Status:
COMPLETED
Last Update Posted:
2019-06-20
First Post:
2014-12-01
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Sponsor:
St. Louis University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SLU IRB 25007
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None